bit.bio is currently building a pipeline of cell therapies focused on areas of unmet clinical need.
As such, the partnership will apply Synthego’s knowledge in gene editing to bit.bio’s opti-ox precision cell programming technology, with the aim of progressing advanced genetic engineering solutions for cell therapies.
Synthego will deliver an end-to-end optimized multiplexed genetic editing strategy. According to the company, the implementation of the multiplexed opti-ox engineering approach will reduce the number of engineering steps required, with the potential of shortening clinical cell engineering and development timelines by up to 10 months.
Paul Dabrowski, CEO at Synthego, said: “bit.bio is the leading synthetic biology company focussed on human cells. We are thrilled to deepen our partnership with bit.bio to facilitate a leap forward in the development of synthetic biology-based cell therapies. By coordinating our respective technologies, expertise and resources, we will unlock new opportunities for addressing critical challenges in the field by advancing the R&D cycle of innovative cell therapies.”
Mark Kotter, CEO at bit.bio, added: “Synthego are experts when it comes to industrialized cell engineering. Teaming up with Synthego will boost our genetic engineering capabilities. We expect efficiency gains across bit.bio’s platform which will allow us and our partners to deliver transformative therapies more rapidly to patients in need."